108 家港股藥企成績單！有人跌超千億，有人暴漲 588%，石藥、百濟、復星、藥明誰起誰落？

E藥經理人
2021.08.27 13:47

整體來看，上半年傳統有產品收入的藥企整體增長明顯放緩，而剛剛步入商業化的藥企業績相對亮眼，但商業化仍難題仍然待解。營收的放緩並沒有影響藥企對研發的投入。大分子藥物仍是各大藥企研發的重點；小分子的創新也同樣是藥企願 “下功夫” 的地方；細胞療法、ADC、mRNA 藥物、PROTAC 等前沿技術已不再是少數者的遊戲，而是各大藥企突破創新瓶頸的重要途徑。

108 家港股藥企成績單！有人跌超千億，有人暴漲 588%，石藥、百濟、復星、藥明誰起誰落？
Source: E藥經理人 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.